interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Patient Assistance › Oral Breast Cancer Drug Assistance
Patient assistance · oncology pills

Oral breast cancer drug assistance in 2026: Ibrance, Kisqali, Verzenio and newer pills

The three independent breast cancer copay funds we checked were closed on 26 October 2026, so the open doors are the makers: copay offers for commercial insurance, free-drug programmes with published income limits, and one 5-month bridge.

terms read 26 Oct 20263 funds closedcopay offers exclude Medicare
Lattice finding · sponsor and fund pages read 26 October 2026

On 26 October 2026 all three independent breast cancer copay funds we checked (CancerCare breast, CancerCare metastatic breast, HealthWell Breast Cancer Medicare Access) were closed to new patients, so for oral breast cancer pills the open door is the maker: free-drug ceilings are $47,880 for one person at Pfizer (300% of the poverty level, for Ibrance) and $79,800 at Lilly Cares (500%, for Verzenio and Inluriyo), and the Ibrance and Kisqali copay offers both exclude Medicare.

Method: we read each maker’s own programme pages, the Lilly Cares application and the three fund pages on 26 October 2026, converted dollar limits to the 2026 HHS poverty guideline ($15,960 for one person in the 48 states), and recorded what each prints and leaves out. How we built this

Quick answer: what help exists for oral breast cancer medicines?

By insurance type:

  1. Commercial insurance: Ibrance savings of $4,000 to $10,000 a year, Kisqali Co-Pay Plus, and Truqap’s co-pay savings (no income requirements) each say as little as $0.
  2. Insurer delays or denies Kisqali: its Bridge Program provides up to 5 months free, for private insurance only.
  3. Medicare or no insurance: the copay offers do not apply. Free-drug routes: Pfizer Patient Assistance Program (Ibrance, up to 300% of the poverty level, including Medicare Part D patients), Lilly Cares Group 4 (Verzenio and Inluriyo, up to 500%), and the Novartis foundation (Kisqali).
  4. Independent funds: CancerCare’s breast and metastatic breast funds and HealthWell’s breast cancer fund were all closed on 26 October 2026.

Which oral breast cancer medicines have support programmes?

Seven oral medicines named on their own sites for breast cancer are covered here. This page compares support programmes only: which medicine suits which patient, and in what order, is a decision for your oncologist.

What each maker publishescopay offer, free-drug route and bridge, read 26 October 2026
What each oral breast cancer medicine's maker publishes: copay offer, free-drug route and bridge. Ibrance $4,000 to $10,000 a year and Pfizer free drug at 300 percent; Kisqali a bridge of up to 5 months; Verzenio and Inluriyo in Lilly Cares Group 4; Truqap no income test for its copay offer; Orserdu no terms on its site.Copay offerFree-drug routeBridgeIbrance$4,000 to $10,000savings a yearPfizer programup to 300%None printedKisqaliAs little as $0limit not printedNovartis foundationrule not printedFree, up to 5 monthsafter a PA denialVerzenioNot readbot wallLilly CaresGroup 4, 500%Not readbot wallInluriyoNot readbot wallLilly CaresGroup 4, 500%Not readbot wallItovebiAsk GenentechAccess SolutionsAsk GenentechAccess SolutionsNone printedTruqapAs little as $0no income testAccess 360hub lineNone printedOrserduNo terms onits siteNo terms onits siteNone printed
Verzenio’s and Inluriyo’s own Lilly sites answered with an access check to every request on 26 October 2026, so no card or bridge terms are printed for them; Kisqali’s and Verzenio’s card maximums are not printed because we did not read a primary source for them.
MedicineMakerSupport as the sponsor words itPhone (sponsor page)
Ibrance (palbociclib)PfizerPfizer Oncology Together: eligible, commercially insured patients may pay as little as $0 per month; savings $4,000 to $10,000 annually. Not for patients enrolled in state or federal programmes, including Medicare, Medicaid, TRICARE and VA. Medicare or uninsured patients: Pfizer Patient Assistance Program, free medicine if eligible.1-877-744-5675
Kisqali (ribociclib)NovartisCo-Pay Plus: private insurance, as little as $0, annual limit not printed. Bridge Program: up to 5 months free for private insurance with a denial based on a prior authorization requirement; submit a prior authorization or appeal within the first 90 days. Not for Medicare, Medicaid or TRICARE. Free-drug route: Novartis Patient Assistance Foundation.866-433-8000
Verzenio (abemaciclib)Eli LillyListed in Lilly Cares Group 4 (income at or below 500% of the poverty level). Card terms not read.Lilly Cares 1-800-545-6962
Inluriyo (imlunestrant)Eli LillyListed in Lilly Cares Group 4. Card terms not read.Lilly Cares 1-800-545-6962
Itovebi (inavolisib)GenentechThe site directs financial questions to Genentech Access Solutions; no terms printed on the page read.1-877-436-3683
Truqap (capivasertib)AstraZenecaCo-Pay Savings Program for eligible, commercially insured patients: as little as $0 per month; no income requirements. AstraZeneca Access 360 answers questions about coverage, costs and patient assistance.1-844-275-2360
Orserdu (elacestrant)Stemline, a Menarini Group companyNo programme terms on the pages read.None on the page read

How do you get them free without insurance?

Pfizer’s Ibrance page says that if Extra Help or other funding is not available, Pfizer Oncology Together will see if you qualify for the Pfizer Patient Assistance Program, which provides prescribed Pfizer Oncology medicines free. Pfizer’s programme update says that for 2026 all patients, including Medicare Part D and Medicare Advantage patients, must have a pre-tax household income at or below 300% of the poverty level, which is $47,880 for one person in the 48 states. Uninsured patients are first checked for Medicaid. Our Pfizer guide has the application steps.

Lilly Cares’s 2026 application puts Verzenio and Inluriyo in Group 4: income at or below 500% of the poverty level ($79,800 for one person, $108,200 for two, $136,600 for three, $165,000 for four). Group 4 patients may be uninsured, on Medicare Part D, on Medicare Part B with no supplemental cover, or insured where the plan does not cover the medicine; applicants cannot be enrolled in Medicaid, full Extra Help or VA benefits. Our Lilly Cares guide covers the programme in full.

Novartis’s foundation lists Kisqali (1-800-277-2254); its pages print no dollar income limit, and our income limits comparison records 400% ($63,840 for one person) from the programme dataset checked 19 October 2026.

Published household income ceilings, one personfree-drug routes, 2026 poverty guideline, read 26 October 2026
Published household income ceilings for one person on the free-drug routes: Pfizer Patient Assistance Program $47,880 (300 percent of the 2026 poverty level) and Lilly Cares Group 4 $79,800 (500 percent); no figure was read for the Novartis foundation (Kisqali), Genentech (Itovebi) or AstraZeneca (Truqap).0$20k$40k$60k$80kPfizer PAP (Ibrance)$47,880 (300%)Lilly Cares Group 4$79,800 (500%)Novartis (Kisqali)figure not on pages readGenentech (Itovebi)figure not readAstraZeneca (Truqap)figure not read
Ceilings are for the 48 contiguous states; Alaska and Hawaii limits are higher. Free-drug programmes can change their limits each January.

Foundation help: CancerCare and HealthWell

Three independent breast cancer copay funds were closed on 26 October 2026. CancerCare’s breast cancer fund and its metastatic breast cancer fund each read “Status: Closed,” with an email sign-up for re-opening; they require insurance and an income at or below 500% of the poverty level, and CancerCare’s FAQ says assistance from its funds can count toward true out-of-pocket costs for the Medicare Part D annual cap. HealthWell’s Breast Cancer Medicare Access fund also read “Closed,” with a $7,500 maximum award and the same 500% income limit; abemaciclib is on its covered-treatment list. We link the live fund pages rather than assert a fund is open.

The independent breast cancer fundsstatus read 26 October 2026
The independent breast cancer copay funds on 26 October 2026: CancerCare breast, CancerCare metastatic breast and HealthWell Breast Cancer Medicare Access were all closed to new patients; each has an income limit of 500 percent of the poverty level.StatusIncome limitInsuranceMax awardCancerCare: breastClosedUp to 500%of poverty levelAny insurancerequiredNot printedCancerCare: metastaticClosedUp to 500%of poverty levelInsurancerequiredNot printedHealthWell: Medicare AccessClosedUp to 500%of poverty levelCopay or Part Bpremium help$7,500
Funds open and close through the year as donations arrive; check the live page before you plan around one.

What if you have Medicare? Ibrance’s 2027 price and the $2,400 cap

The Ibrance and Kisqali copay offers exclude Medicare, so Medicare patients rely on the free-drug routes above, Extra Help and Part D’s own limits. Medicare has negotiated a price for Ibrance that takes effect in 2027: CMS’s fact sheet lists a 30-day negotiated price of $7,871 against a list price of $15,741 (50% lower). That is the price Medicare plans pay, not your copay: out-of-pocket spending on covered Part D drugs is capped at $2,400 in 2027 (Medicare.gov). Our 2027 negotiated prices guide covers all 15 drugs. All seven medicines above were listed on all 328 Part D formularies in CMS’s September 2026 file; a listing still does not tell you whether prior authorization applies.

Ibrance under Medicare in 2027CMS fact sheet (initial price applicability year 2027) and Medicare.gov
Ibrance in 2027 under Medicare: list price $15,741 for a 30-day supply, Medicare negotiated price $7,871 (a 50 percent discount), and the whole-year out-of-pocket cap on covered Part D drugs of $2,400.0$4k$8k$12k$16kList price, 30 days$15,741Negotiated, 30 days$7,871Yearly out-of-pocket cap$2,400
The cap applies to covered Part D drugs across the whole year, so for a drug priced like this one the cap, not the negotiated price, sets what an enrollee can pay. Your plan’s deductible and coinsurance still apply until you reach it.

What should you ask when you call?

Call sheet: oral breast cancer medicine cost help (keep this)
Medicine: ______________   Insurance type: ______________   Date: ________
Commercial insurance:
[ ] Is the copay offer open to me? What is the yearly limit? What ends it?
[ ] Insurer delaying or denying? Is there a bridge? (Kisqali: up to 5 months; file within 90 days)
[ ] Does a copay maximizer or accumulator plan change what the offer pays?
Medicare, Medicaid, or no insurance:
[ ] Which free-drug programme covers this medicine and what is the income limit?
    (Pfizer: 300% of the poverty level, $47,880 for one person. Lilly Cares Group 4: 500%, $79,800.)
[ ] Medicare: do I need an Extra Help denial first?
Independent funds: check CancerCare and HealthWell for a re-opened fund, and sign up for alerts.
Numbers on the sponsors' own pages (26 Oct 2026):
Pfizer Oncology Together 1-877-744-5675  |  Kisqali 866-433-8000  |  Truqap Access 360 1-844-275-2360
Genentech Access Solutions 1-877-436-3683  |  Lilly Cares 1-800-545-6962

What should you do, by situation?

  • If you have commercial insuranceEnrol in the maker’s copay offer on the day your oncologist chooses the medicine, and ask the hub whether a copay maximizer or accumulator plan changes what it pays.
  • If you have MedicareNo copay offer applies. Ask the free-drug programme for your medicine (Pfizer takes Medicare Part D patients up to 300%; Lilly Cares takes them up to 500%), and check Extra Help, which Pfizer and Novartis both ask about first.
  • If you have no insuranceApply to the maker’s free-drug programme and check Medicaid at the same time; Pfizer checks Medicaid first.
  • If you were counting on a foundation grantAll three independent breast cancer funds are closed today; register for the re-opening alerts and use a maker route meanwhile.
How we built this

We read each programme’s own eligibility page, application form or terms on 26 October 2026 (Ibrance and Pfizer’s programme update, Kisqali, Itovebi, Truqap, Orserdu, the Lilly Cares 2026 application, CancerCare and HealthWell fund pages), converted dollar limits to percentages of the 2026 HHS poverty guideline, and drew on the CMS 2027 negotiated price fact sheet (compared byte for byte with our saved copy) and CMS’s September 2026 Part D formulary file. We did not apply to any programme. Where a programme does not publish a figure, we say so rather than estimate it; Lilly’s oncology sites were unreachable and are not quoted. We compare support programmes, never treatments. OmniRx does not employ named credentialed reviewers; this is patient-navigation reference, not medical advice. Full policy.

Related: cancer drug assistance overview, bridge programmes compared and the assistance finder.

Frequently asked questions

Are there free programmes for oral breast cancer drugs without insurance?

Yes, from the makers. Pfizer's Patient Assistance Program (Ibrance) requires income at or below 300% of the 2026 poverty level, $47,880 for one person; Lilly Cares (Verzenio and Inluriyo, Group 4) allows up to 500%, $79,800 for one person; the Novartis Patient Assistance Foundation lists Kisqali. Each decides eligibility itself.

Can I use the Ibrance or Kisqali copay card with Medicare?

No. Ibrance's savings are not for patients enrolled in state or federal programmes including Medicare, Medicaid, TRICARE and VA, and Kisqali's Co-Pay Plus is not valid under Medicare, Medicaid, TRICARE or VA. Medicare patients use the free-drug routes and Extra Help.

Is the CancerCare or HealthWell breast cancer fund open?

Not on 26 October 2026. CancerCare's breast cancer and metastatic breast cancer funds and HealthWell's Breast Cancer Medicare Access fund each read "Closed" on their own pages. Each has a 500% poverty-level income limit. Check the live pages, which change as donations arrive.

Does Kisqali offer a bridge if my insurer delays coverage?

Kisqali's Bridge Program provides up to 5 months free for patients with private insurance and a denial based on a prior authorization requirement, if a prior authorization or appeal is submitted within the first 90 days. It is not available to patients on Medicare, Medicaid or TRICARE.

What is Ibrance's Medicare price in 2027?

CMS's fact sheet lists a 30-day negotiated price of $7,871 for Ibrance in 2027 against a list price of $15,741, which is 50% lower. That is what Medicare plans pay; a Part D enrollee's yearly out-of-pocket spending on covered drugs is capped at $2,400 in 2027.

The bottom line

For oral breast cancer medicines the open doors are the makers: commercial copay offers (Ibrance $4,000 to $10,000 a year; Kisqali and Truqap as little as $0), a 5-month Kisqali bridge, and free-drug programmes with a 300% ceiling at Pfizer and 500% at Lilly Cares. The three independent breast cancer funds we checked were closed on 26 October 2026, and none of the copay offers works with Medicare.

Sources

  1. Pfizer. IBRANCE financial support and Pfizer Oncology Together. ibrance.com checked 2026-10-26
  2. Pfizer. Pfizer Patient Assistance Program updates (2026 income requirement). pfizerrxpathways.com checked 2026-10-26
  3. Novartis. KISQALI Novartis Patient Support (Co-Pay Plus, Bridge Program). us.kisqali.com checked 2026-10-26
  4. Lilly Cares Foundation. Lilly Cares application (2026 income table, Group 4 medications). lillycares.com checked 2026-10-26
  5. Genentech. Itovebi financial support. itovebi.com checked 2026-10-26
  6. AstraZeneca. TRUQAP financial support and Access 360. truqap.com checked 2026-10-26
  7. Stemline Therapeutics. ORSERDU patient site. orserdu.com checked 2026-10-26
  8. CancerCare. Co-Payment Assistance Foundation: breast cancer fund. cancercare.org checked 2026-10-26
  9. CancerCare. Co-Payment Assistance Foundation: metastatic breast cancer fund. cancercare.org checked 2026-10-26
  10. HealthWell Foundation. Breast Cancer Medicare Access fund. healthwellfoundation.org checked 2026-10-26
  11. Centers for Medicare & Medicaid Services. Negotiated prices for initial price applicability year 2027 (fact sheet). cms.gov checked 2026-10-26
  12. Medicare.gov. Costs for Medicare drug coverage ($2,400 cap in 2027). medicare.gov checked 2026-10-26
  13. HHS ASPE. 2026 poverty guidelines. aspe.hhs.gov checked 2026-10-26
OmniRx

Cancer Drug Assistance Overview

Manufacturer programmes and foundations across cancers.

Programmeread
 OmniRx

Medicare Negotiated Prices 2027

All 15 drugs, list vs negotiated, and what you pay.

Articleread
 OmniRx

Lilly Cares Foundation

Medication groups, income limits and how to apply.

Programmeread